Aptabio Therapeutics Inc
293780
Company Profile
Business description
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.
Contact
13, Heungdeok 1-ro, Giheung-gu
Tower 504, Gyeonggi-do
Yongin-Si16954
KORT: +82 7071520097
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,768.60 | 1.60 | -0.02% |
| CAC 40 | 7,790.27 | 14.40 | -0.18% |
| DAX 40 | 24,323.58 | 47.10 | 0.19% |
| Dow JONES (US) | 42,437.74 | 10.00 | 0.02% |
| FTSE 100 | 8,811.04 | 9.75 | 0.11% |
| HKSE | 23,906.97 | 252.94 | 1.07% |
| NASDAQ | 19,418.99 | 41.50 | -0.21% |
| Nikkei 225 | 37,554.49 | 192.96 | -0.51% |
| NZX 50 Index | 12,577.15 | 82.44 | 0.66% |
| S&P 500 | 5,961.68 | 9.13 | -0.15% |
| S&P/ASX 200 | 8,538.90 | 2.90 | -0.03% |
| SSE Composite Index | 3,384.10 | 7.90 | 0.23% |